Jesús
San Miguel Izquierdo
Consultor Investigador
University Hospital Brno
Brno, República ChecaPublicaciones en colaboración con investigadores/as de University Hospital Brno (6)
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
BMC Cancer, Vol. 21, Núm. 1
2020
-
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
The Lancet, Vol. 395, Núm. 10218, pp. 132-141
-
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia, Vol. 34, Núm. 2, pp. 589-603
2019
-
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Blood, Vol. 133, Núm. 18, pp. 1953-1963
2018
-
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
New England Journal of Medicine, Vol. 378, Núm. 6, pp. 518-528